Clinical Trial Search

Primary: Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los…

Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants

Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00

Primary: Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N) — 58.8; 78.4; 77.0 Percentage of…

Primary: Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score — 15.5 score on a scale

Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…

Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants

Primary: Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. — 94.9; 87.3 percentage of participants

Primary: Number of Participants Who Responded — 7; 4 participants

Primary: Percentage of Participants With Healing of RE Who Were Graded "O" at Week 8 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles…

Primary: Number of Participants With Treatment Failure at 5 Years — 33; 19 participants

Primary: Percent Change in the Reflux Symptom Index (RSI) at 4 Weeks — -54.3 Per Cent Change — p=<0.05

Primary: Number of Transient Lower Esophageal Sphincter Relaxations (TLESRs) 0-3 Hours Post Meal, Post Third Dose — 11.6; 15.5 Relaxations

Primary: Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study. — 34.3; 10.4 Percentage of participants

Primary: Patient's Assessment of Stanford Sleepiness Scale for the Last 24 Hours (Diaries) — 2.94; 2.62; 2.28; 2.03 Units on a scale

Primary: Forced Vital Capacity (FVC) — -0.13; -0.05 liters

Primary: Number of Impedance Episodes Following PPI and Placebo — 47; 53 number of episodes

Primary: Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment — -3.44 Days per week with symptoms

Primary: Time to First Pulmonary Exacerbation — NA; NA Weeks

Primary: Efficacy of Three Strategies of Long-term Treatment — 10.6; 7.8; 43 Percentage of participants with failure

Primary: The Number of Reflux in GERD Patients — 33.6; 42.8; 81.0; 53.1 episodes — p=0.002

Primary: Percentage of Participants Completely Cured of Reflux Esophagitis Evaluated by Endoscopy Based on CYP2C19 — 97.37; 93.94; 100.00; 100.00 Percentage of participants…

Primary: The Rates of Complete Symptom Relief — 152; 157 participants — p=<0.05

Primary: Number of Patients With Esophageal Mucosa Healing — 28; 28; 32; 18 Participants

Primary: Patient's Assessment of General Well-being During the Last 24 Hours (Diaries; ReQuest™ in Practice) — 5.31; 4.60; 3.67; 2.95 Units on a scale

Primary: Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS) — 17.9; 17.2 VAS (100)

Primary: Assessment of the Severity of Sleep Disturbances — 13.8; 77.4; 38.2; 20.0 percentage of participants

Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…

Primary: Change From Baseline in Reflux Disease Symptom - Heartburn — 59; 117; 186; 7 participants

Primary: Number of Participants With Complete Response to Dysphagia — 9; 6 participants — p=0.74